Enliven Therapeutics, Inc. <ELVN.O>: Guggenheim cuts target price to $78 from $80
ELVN•Related News
Tarsus Pharmaceuticals to report Q2 2026 results, host webcast
TARS•
BTG Pactual declares BRL 0.21 net interest on equity per share
BPAC•
E.l.f. Beauty, Inc. <ELF.N>: Piper Sandler Raises Target Price to $65 From $50
ELF•
Protagonist Therapeutics, Inc. <PTGX.O>: Leerink Partners raises target price to $150.00 from $110.00
PTGX•
Chori signs exclusive Japan distribution deal with India’s RCMPA for cerium compounds
SOXX•